Search Results - "Moskowitz, H."

Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma by Chen, Robert, Zinzani, Pier Luigi, Fanale, Michelle A, Armand, Philippe, Johnson, Nathalie A, Brice, Pauline, Radford, John, Ribrag, Vincent, Molin, Daniel, Vassilakopoulos, Theodoros P, Tomita, Akihiro, von Tresckow, Bastian, Shipp, Margaret A, Zhang, Yinghua, Ricart, Alejandro D, Balakumaran, Arun, Moskowitz, Craig H

“…Purpose Hodgkin Reed-Sternberg cells harbor alterations in chromosome 9p24.1, leading to overexpression of programmed death-ligand 1 (PD-L1) and PD-L2…”
Get full text

Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087 by Chen, Robert, Zinzani, Pier Luigi, Lee, Hun Ju, Armand, Philippe, Johnson, Nathalie A., Brice, Pauline, Radford, John, Ribrag, Vincent, Molin, Daniel, Vassilakopoulos, Theodoros P., Tomita, Akihiro, von Tresckow, Bastian, Shipp, Margaret A., Lin, Jianxin, Kim, Eunhee, Nahar, Akash, Balakumaran, Arun, Moskowitz, Craig H.

“…Programmed death-1 inhibitors are approved for patients with relapsed or refractory classic Hodgkin lymphoma (RRcHL). We present the 2-year follow-up of the…”
Get full text

Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse by Moskowitz, Craig H., Walewski, Jan, Nademanee, Auayporn, Masszi, Tamas, Agura, Edward, Holowiecki, Jerzy, Abidi, Muneer H., Chen, Andy I., Stiff, Patrick, Viviani, Simonetta, Bachanova, Veronika, Sureda, Anna, McClendon, Teresa, Lee, Connie, Lisano, Julie, Sweetenham, John

“…The phase 3 AETHERA trial established brentuximab vedotin (BV) as a consolidative treatment option for adult patients with classical Hodgkin lymphoma (cHL) at…”
Get full text

Transplant strategies in relapsed/refractory Hodgkin lymphoma by Shah, Gunjan L., Moskowitz, Craig H.

“…The majority of patients with Hodgkin lymphoma (HL) are cured with initial therapy. However, high-dose therapy with autologous hematopoietic cell transplant…”
Get full text

Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era by GISSELBRECHT, Christian, GLASS, Bertram, MA, David, BRIERE, Josette, MOSKOWITZ, Craig H, SCHMITZ, Norbert, MOUNIER, Nicolas, SINGH GILL, Devinder, LINCH, David C, TRNENY, Marek, BOSLY, Andre, KETTERER, Nicolas, SHPILBERG, Ofer, HAGBERG, Hans

“…Salvage chemotherapy followed by high-dose therapy and autologous stem-cell transplantation (ASCT) is the standard treatment for relapsed diffuse large B-cell…”
Get full text

Patient-centered care in telemedicine – An experimental-design study by Gabay, G., Ornoy, H., Moskowitz, H.

“…•There are three distinct mindsets of patients' expectations.•Members of each mindset have different expectations of providers in telemedicine.•Providers may…”
Get full text

Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma by YOUNES, Anas, GOPAL, Ajay K, FORERO-TORRES, Andres, MOSKOWITZ, Craig H, CONNORS, Joseph M, ENGERT, Andreas, LARSEN, Emily K, KENNEDY, Dana A, SIEVERS, Eric L, CHEN, Robert, SMITH, Scott E, ANSELL, Stephen M, ROSENBLATT, Joseph D, SAVAGE, Kerry J, RAMCHANDREN, Radhakrishnan, BARTLETT, Nancy L, CHESON, Bruce D, DE VOS, Sven

“…Brentuximab vedotin is an antibody-drug conjugate (ADC) that selectively delivers monomethyl auristatin E, an antimicrotubule agent, into CD30-expressing…”
Get full text

Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial by Moskowitz, Craig H, Dr Prof, Nademanee, Auayporn, Prof, Masszi, Tamas, Prof, Agura, Edward, Prof, Holowiecki, Jerzy, Prof, Abidi, Muneer H, Prof, Chen, Andy I, Prof, Stiff, Patrick, Prof, Gianni, Alessandro M, Prof, Carella, Angelo, Prof, Osmanov, Dzhelil, Prof, Bachanova, Veronika, Prof, Sweetenham, John, Prof, Sureda, Anna, Prof, Huebner, Dirk, MD, Sievers, Eric L, MD, Chi, Andy, PhD, Larsen, Emily K, MS, Hunder, Naomi N, MD, Walewski, Jan, Prof

“…Summary Background High-dose therapy followed by autologous stem-cell transplantation is standard of care for patients with relapsed or primary refractory…”
Get full text

Rituximab Maintenance Therapy After Autologous Stem-Cell Transplantation in Patients With Relapsed CD20+ Diffuse Large B-Cell Lymphoma: Final Analysis of the Collaborative Trial in Relapsed Aggressive Lymphoma by GISSELBRECHT, Christian, SCHMITZ, Norbert, SHPILBERG, Ofer, DÜHRSEN, Ulrich, HAGBERG, Hans, MA, David D, VIARDOT, Andreas, LOWENTHAL, Ray, BRIERE, Josette, SALLES, Gilles, MOSKOWITZ, Craig H, GLASS, Bertram, MOUNIER, Nicolas, SINGH GILL, Devinder, LINCH, David C, TRNENY, Marek, BOSLY, Andre, MILPIED, Noel J, RADFORD, John, KETTERER, Nicolas

“…The standard treatment for relapsed diffuse large B-cell lymphoma (DLBCL) is salvage chemotherapy followed by high-dose therapy and autologous stem-cell…”
Get full text

Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma by Sauter, Craig S., Matasar, Matthew J., Meikle, Jessica, Schoder, Heiko, Ulaner, Gary A., Migliacci, Jocelyn C., Hilden, Patrick, Devlin, Sean M., Zelenetz, Andrew D., Moskowitz, Craig H.

“…High-dose chemotherapy (HDT) plus autologous stem cell transplantation (ASCT) is the standard of care for chemosensitive relapsed and refractory diffuse large…”
Get full text

CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET by Straus, David J., Jung, Sin-Ho, Pitcher, Brandelyn, Kostakoglu, Lale, Grecula, John C., Hsi, Eric D., Schöder, Heiko, Popplewell, Leslie L., Chang, Julie E., Moskowitz, Craig H., Wagner-Johnston, Nina, Leonard, John P., Friedberg, Jonathan W., Kahl, Brad S., Cheson, Bruce D., Bartlett, Nancy L.

“…A negative interim positron emission tomography/computerized tomography (PET/CT) after 1 to 3 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine…”
Get full text

Treatment of relapsed and refractory Hodgkin Lymphoma by von Tresckow, Bastian, Moskowitz, Craig H

“…Abstract Despite the high first-line cure rates in patients with Hodgkin Lymphoma (HL) still 10%–20% of patients suffer from relapsed or refractory disease…”
Get full text

Phase II Study of Bendamustine in Relapsed and Refractory Hodgkin Lymphoma by MOSKOWITZ, Alison J, HAMLIN, Paul A, GRAUSTEIN, Tricia, ZELENETZ, Andrew D, MOSKOWITZ, Craig H, PERALES, Miguel-Angel, GERECITANO, John, HORWITZ, Steven M, MATASAR, Matthew J, NOY, Ariela, LIA PALOMBA, Maria, PORTLOCK, Carol S, STRAUS, David J

“…Limited data exist regarding the activity of bendamustine in Hodgkin lymphoma (HL). This phase II study evaluated the efficacy of bendamustine in relapsed and…”
Get full text

Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study by Van Den Neste, E, Schmitz, N, Mounier, N, Gill, D, Linch, D, Trneny, M, Bouadballah, R, Radford, J, Bargetzi, M, Ribrag, V, Dührsen, U, Ma, D, Briere, J, Thieblemont, C, Bachy, E, Moskowitz, C H, Glass, B, Gisselbrecht, C

“…In the CORAL study, 255 chemosensitive relapses with diffuse large B-cell lymphoma (DLBCL) were consolidated with autologous stem cell transplantation (ASCT),…”
Get full text

Phase III Randomized Study of Rituximab/Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) Compared With Iodine-131 Tositumomab/BEAM With Autologous Hematopoietic Cell Transplantation for Relapsed Diffuse Large B-Cell Lymphoma: Results From the BMT CTN 0401 Trial by VOSE, Julie M, CARTER, Shelly, HOROWITZ, Mary, FISHER, Richard, TOMBLYN, Marcie, BURNS, Linda J, AYALA, Ernesto, PRESS, Oliver W, MOSKOWITZ, Craig H, STADTMAUER, Edward A, MINESHI, Shin, AMBINDER, Richard, FENSKE, Timothy

“…This clinical trial evaluated standard-dose radioimmunotherapy with a chemotherapy-based transplantation regimen followed by autologous hematopoietic cell…”
Get full text

PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study by Moskowitz, Alison J, Dr, Schöder, Heiko, Prof, Yahalom, Joachim, Prof, McCall, Susan J, NP, Fox, Stephanie Y, BS, Gerecitano, John, MD, Grewal, Ravinder, MD, Hamlin, Paul A, MD, Horwitz, Steven, MD, Kobos, Rachel, MD, Kumar, Anita, MD, Matasar, Matthew, MD, Noy, Ariela, MD, Palomba, M Lia, MD, Perales, Miguel-Angel, MD, Portlock, Carol S, Prof, Sauter, Craig, MD, Shukla, Neerav, MD, Steinherz, Peter, Prof, Straus, David, Prof, Trippett, Tanya, MD, Younes, Anas, Prof, Zelenetz, Andrew, Prof, Moskowitz, Craig H, Prof

“…Summary Background Pre-transplantation18 F-fluorodeoxyglucose (FDG) PET-negativity is one of the strongest predictors of outcome after high-dose therapy and…”
Get full text

Risk-Adapted Dose-Dense Immunochemotherapy Determined by Interim FDG-PET in Advanced-Stage Diffuse Large B-Cell Lymphoma by MOSKOWITZ, Craig H, SCHÖDER, Heiko, HORWITZ, Steven, WEAVER, Sarah A, MEIKLE, Jessica L, FILIPPA, Daniel A, CARAVELLI, James F, HAMLIN, Paul A, ZELENETZ, Andrew D, TERUYA-FELDSTEIN, Julie, SIMA, Camelia, IASONOS, Alexia, PORTLOCK, Carol S, STRAUS, David, NOY, Ariela, PALOMBA, Maria L, O'CONNOR, Owen A

“…PURPOSE In studies of diffuse large B-cell lymphoma, positron emission tomography with [(18)F]fluorodeoxyglucose (FDG-PET) performed after two to four cycles…”
Get full text

Definition of bulky disease in early stage Hodgkin lymphoma in computed tomography era: prognostic significance of measurements in the coronal and transverse planes by Kumar, Anita, Burger, Irene A, Zhang, Zhigang, Drill, Esther N, Migliacci, Jocelyn C, Ng, Andrea, LaCasce, Ann, Wall, Darci, Witzig, Thomas E, Ristow, Kay, Yahalom, Joachim, Moskowitz, Craig H, Zelenetz, Andrew D

“…Disease bulk is an important prognostic factor in early stage Hodgkin lymphoma, but its definition is unclear in the computed tomography era. This…”
Get full text

Erratum to: Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation by Epstein-Peterson, Zachary D, Drill, Esther, Aypar, Umut, Batlevi, Connie Lee, Caron, Philip, Dogan, Ahmet, Drullinsky, Pamela, Gerecitano, John, Hamlin, Paul A, Ho, Caleb, Jacob, Allison, Joseph, Ashlee, Laraque, Leana, Matasar, Matthew J, Moskowitz, Alison J, Moskowitz, Craig H, Mullins, Chelsea, Owens, Colette, Salles, Gilles, Schöder, Heiko, Straus, David J, Younes, Anas, Zelenetz, Andrew D, Kumar, Anita

Get full text

Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation by Epstein-Peterson, Zachary D, Drill, Esther, Aypar, Umut, Batlevi, Connie Lee, Caron, Philip, Dogan, Ahmet, Drullinsky, Pamela, Gerecitano, John, Hamlin, Paul A, Ho, Caleb, Jacob, Allison, Joseph, Ashlee, Laraque, Leana, Matasar, Matthew J, Moskowitz, Alison J, Moskowitz, Craig H, Mullins, Chelsea, Owens, Colette, Salles, Gilles, Schöder, Heiko, Straus, David J, Younes, Anas, Zelenetz, Andrew D, Kumar, Anita

“…Chemoimmunotherapy followed by consolidative high-dose therapy with autologous stem cell rescue was a standard upfront treatment for fit patients with mantle…”
Get full text